Published in Anticancer Res on May 31, 2000
The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy. Eur J Nucl Med Mol Imaging (2004) 1.56
Usefulness of lymphoscintigraphy and intraoperative gamma probe detection in the identification of sentinel nodes in cervical cancer. Eur J Nucl Med Mol Imaging (2003) 1.41
Sentinel node procedure in Ib cervical cancer: a preliminary series. Br J Cancer (2001) 0.83
Usefulness of sentinel lymph node detection in early stages of cervical cancer. Eur J Nucl Med Mol Imaging (2005) 0.77
Sentinel lymph nodes in gynaecological malignancies: frontline between TNM and clinical staging systems? Eur J Nucl Med Mol Imaging (2003) 0.76
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet (2001) 4.16
Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res (2000) 2.83
Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet (1999) 1.96
Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases. Am J Surg Pathol (1990) 1.78
Serum levels of the tumour-associated trypsin inhibitor in patients with endometriosis. Br J Obstet Gynaecol (1997) 1.59
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet (1996) 1.58
Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.45
Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Gynecol Oncol (1997) 1.42
Adjuvant tamoxifen in postmenopausal stage II breast cancer five years on. Lancet (1990) 1.41
Clonogenic growth in vitro: an independent biologic prognostic factor in ovarian carcinoma. J Clin Oncol (1991) 1.41
[Tumoral vascular density in breast tumors and their effect on recurrence-free survival]. Chirurg (1994) 1.40
Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study. Cancer Invest (2006) 1.39
[Adjuvant hormonal therapy in lymph node-negative breast carcinoma patients in the postmenopause]. Dtsch Med Wochenschr (1992) 1.39
EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res (1997) 1.26
Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol (1995) 1.17
Calibration processes in desert ant navigation: vector courses and systematic search. J Comp Physiol A Neuroethol Sens Neural Behav Physiol (2002) 1.17
A CA125 score as a prognostic index in patients with ovarian cancer. Arch Gynecol Obstet (1990) 1.09
Three-dimensional video-endoscopy: clinical use in gynaecological laparoscopy. Lancet (1994) 1.07
Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas. Mod Pathol (2000) 1.06
Induction and repair of formaldehyde-induced DNA-protein crosslinks in repair-deficient human cell lines. Mutagenesis (2000) 1.04
Light chain myeloma with oro-pharyngeal amyloidosis presenting as bulbar paralysis. J Neurol Sci (1997) 1.01
The influence of obesity on the disease-free survival in primary breast cancer. Anticancer Res (1996) 1.00
Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia (2007) 0.99
Classification of intestinal T-cell neoplasms and their differential diagnosis. Am J Clin Pathol (1999) 0.99
Color-coded and spectral Doppler flow in breast carcinomas--relationship with the tumor microvasculature. Breast Cancer Res Treat (1998) 0.97
Metastasis of solid tumors in extraocular muscles. Acta Neuropathol (1984) 0.96
The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer (1998) 0.96
The impact of trauma centre designation on open tibial fracture management. Ann R Coll Surg Engl (2013) 0.95
Pregnancy-related changes of carnitine and acylcarnitine concentrations of plasma and erythrocytes. J Perinat Med (1995) 0.95
First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer. Br J Cancer (1993) 0.93
Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group. Blood (1999) 0.91
Ultrasonographic tissue characterization in monitoring tumor response to neoadjuvant chemotherapy in locally advanced breast cancer (work in progress). J Ultrasound Med (2000) 0.91
Lunar phases and survival of breast cancer patients--a statistical analysis of 3,757 cases. Breast Cancer Res Treat (2001) 0.91
Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer. Cancer Immunol Immunother (1988) 0.90
Fibroadenomas: computer-assisted quantitative evaluation of contrast-enhanced power Doppler features and correlation with histopathology. Ultrasound Med Biol (2001) 0.89
CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer (1999) 0.88
Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. Int J Cancer (1995) 0.88
[Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers]. Geburtshilfe Frauenheilkd (1985) 0.88
Breast cancer and timing of surgery during menstrual cycle. A 5-year analysis of 385 pre-menopausal women. Int J Cancer (1992) 0.87
Prognostic factors related to recurrent endometrial carcinoma following initial surgery. Acta Obstet Gynecol Scand (1993) 0.87
Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep (2000) 0.86
The application of fibrin glue after axillary lymphadenectomy in the surgical treatment of human breast cancer. Anticancer Res (1996) 0.86
A comparative analysis of management and prognosis in stage I and II fallopian tube carcinoma and epithelial ovarian cancer. Br J Cancer (1994) 0.86
Alterations in Krebs cycle enzyme activities and carbohydrate catabolism in two strains of Trypanosoma brucei during in vitro differentiation of their bloodstream to procyclic stages. Mol Biochem Parasitol (1991) 0.85
Influence of delayed diagnosis on established prognostic factors in endometrial cancer. Anticancer Res (1996) 0.85
A systematic review of free tissue transfer in the management of non-traumatic lower extremity wounds in patients with diabetes. Eur J Vasc Endovasc Surg (2010) 0.83
A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone. Leukemia (1996) 0.83
Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur J Cancer (2003) 0.83
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice. Support Care Cancer (2013) 0.83
Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia (2005) 0.82
Malignant pleural and pericardial effusion in invasive breast cancer: impact of the site of the primary tumor. Breast Cancer Res Treat (2004) 0.82
Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. Acta Obstet Gynecol Scand (2001) 0.82
Thrombosis with paclitaxel. Lancet (1994) 0.82
Antenatal betamethasone-dose-effects on fetal rat lung morphology and surfactant. J Perinat Med (1994) 0.81
Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol (1997) 0.81
Influence of delayed staging laparotomy after laparoscopic removal of ovarian masses later found malignant. Obstet Gynecol (1998) 0.81
pS2 protein status fails to be an independent prognostic factor in an average breast cancer population. Anticancer Res (1995) 0.81
[Long-term analysis of disability pensions in survivors of the Holocaust: somatic and psychiatric diagnoses]. Fortschr Neurol Psychiatr (2010) 0.81
DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Gynecol Oncol (1995) 0.80
[Hypoglycemic and hyperinsulinemic clamp technic to determine the secretory behavior of insulinoma]. Dtsch Med Wochenschr (1988) 0.80
Pleural and bone marrow metastasis from supratentorial oligoastrocytoma grade III. Oncology (1998) 0.79
Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer. Onkologie (1989) 0.79
[Carnitine levels in pregnancy]. Z Geburtshilfe Perinatol (1989) 0.79
The influence of temperature during alkaline treatment and electrophoresis on results obtained with the comet assay. Toxicol Lett (1999) 0.79
Radioimmunoscintigraphy using monoclonal antibodies before second-look surgery in patients suffering from ovarian cancer. Gynecol Obstet Invest (1987) 0.79
[Ferritin level in newborn infants after prepartal iron medication]. Geburtshilfe Frauenheilkd (1991) 0.79
Mutagen sensitivity of human lymphoblastoid cells with a BRCA1 mutation in comparison to ataxia telangiectasia heterozygote cells. Cytogenet Cell Genet (2000) 0.79
[Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients]. Geburtshilfe Frauenheilkd (1985) 0.79
[The sympathetic axons of the nerves of the hand]. Handchir Mikrochir Plast Chir (2002) 0.78
The nerve of Henle: an anatomic and immunohistochemical study. J Hand Surg Am (1999) 0.78
TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer. Anticancer Res (1999) 0.78
Psammocarcinoma of the peritoneum diagnosed during operative laparoscopy. Acta Obstet Gynecol Scand (1998) 0.78
Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. Eur J Cancer (1995) 0.78
In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma. Cancer (1993) 0.78
Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer (1998) 0.78
Low-grade mucosa-associated lymphoma of the breast: radiological-pathological correlation. Eur Radiol (2001) 0.78
Association of increased lytic effector cell function with high estrogen receptor levels in tumor-bearing patients with breast cancer. Cancer (1989) 0.78
Prognostic significance of cell DNA content in early-stage ovarian cancer (FIGO stages I and II/A) by means of automatic image cytometry. Int J Cancer (1994) 0.78
Laparoscopic surgery in cases of ovarian malignancies: an Austria-wide survey. Gynecol Oncol (1996) 0.78
Adventitial stripping of the radial and ulnar arteries in Raynaud's disease. J Hand Surg Am (2002) 0.78
[Therapeutic and prognostic results of a prospective multicenter ovarian cancer study of FIGO stages I and II]. Geburtshilfe Frauenheilkd (1987) 0.77
[Tumor vascular invasion in breast carcinoma. Hematoxylin-eosin versus immunohistochemical staining for factor VIII antigen]. Dtsch Med Wochenschr (1994) 0.77
Comparative evaluation of the genotoxic properties of potassium bromate and potassium superoxide in V79 Chinese hamster cells. Mutat Res (1999) 0.77
[Therapy studies of the Austrian Breast Cancer Group (ABC)]. Zentralbl Chir (1998) 0.77
Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer. Br J Cancer (2005) 0.77
In vitro endothelialization of expanded polytetrafluoroethylene grafts: a clinical case report after 41 months of implantation. J Vasc Surg (1997) 0.77
[Labor induction with 3 mg of prostaglandin E2 vaginal tablets. A renaissance of programmed labor? Results of a prospective randomized study]. Geburtshilfe Frauenheilkd (1986) 0.77
First experiences with intraperitoneal chemotherapy in ovarian cancer. Eur J Gynaecol Oncol (1990) 0.77
HER-2 amplification but not butyrylcholinesterase multability reflects aggressiveness of European-originated ovarian tumors. Gynecol Oncol (1995) 0.76
[Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy]. Gynakol Rundsch (1990) 0.76
[Surgery in the treatment concept of epithelial ovarian cancer]. Gynakol Rundsch (1990) 0.76
In vitro endothelialization of a mesosystemic shunt: a clinical case report. J Vasc Surg (1994) 0.75
TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer. Br J Cancer (1995) 0.75
Safety of vagus nerve stimulation in a patient with bipolar disorder and an implanted cardioverter-defibrillator. Acta Neurol Scand (2010) 0.75
Mesenteric venous thrombosis with protein S deficiency. Am J Gastroenterol (1993) 0.75
Magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. Anticancer Res (1995) 0.75